RTTNews’ Post

Do you work in the cell therapy❓- 𝗧𝗼𝗱𝗮𝘆 𝗶𝘀 𝘆𝗼𝘂𝗿 𝗙𝗜𝗡𝗔𝗟 𝗖𝗛𝗔𝗡𝗖𝗘 to 𝘀𝗲𝗰𝘂𝗿𝗲 𝗼𝘂𝗿 𝗵𝗶𝗴𝗵𝗲𝘀𝘁 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁𝘀 𝗼𝗳 𝘂𝗽 𝘁𝗼 $𝟭,𝟭𝟬𝟬 - https://ter.li/t2kq70 for the 𝟲𝘁𝗵 𝗠𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲-𝗗𝗶𝗿𝗲𝗰𝘁𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗦𝘂𝗺𝗺𝗶𝘁!   This is a once-a-year opportunity to 𝗰𝗼𝗻𝗻𝗲𝗰𝘁 𝘄𝗶𝘁𝗵 𝗸𝗲𝘆 𝗽𝗹𝗮𝘆𝗲𝗿𝘀 from Carisma Therapeutics, ALX Oncology, NextPoint Therapeutics, Inc., Elpiscience Biopharmaceuticals, and more to unleash the full potential of your macrophage therapeutics and stay ahead of the curve.🤝   We also offer 𝗮𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗴𝗿𝗼𝘂𝗽 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁𝘀 𝗼𝗳 𝘂𝗽 𝘁𝗼 𝟮𝟬%, which you can explore in our full agenda - https://ter.li/9vo845   Don't let this valuable opportunity slip away! 𝗕𝗼𝗼𝗸 𝗯𝗲𝗳𝗼𝗿𝗲 𝗺𝗶𝗱𝗻𝗶𝗴𝗵𝘁 𝘁𝗼 𝘀𝗮𝘃𝗲 $𝟭,𝟭𝟬𝟬, and make a real impact this year at the #MacrophageDirectedTherapiesSummit

Solid tumors are a massive challenge for CAR-T - until now? "The first documented complete response in a patient with a solid tumour treated with CAR-T therapy" was reported by AffyImmune Therapeutics. This all came out as part of the deluge of ASCO (American Society of Clinical Oncology) abstracts that were unveiled last week. It's a Phase 1 so we're not popping the champagne yet - but it's a step in the right direction! Article and more deets in the comments below ⬇️ —————————— Comprehensive, daily coverage of the biotech and pharma industry, straight to your inbox (and all in one email) - that's TLDR Biotech. 🧬🔔 #biotech #pharma #pharmanews #biotechnews #tldrbiotech

Dr. Roy Baynes of Eikon Therapeutics joined us to discuss his process of developing pembrolizumab, also known as Keytruda. Applying his experience as CMO and Head of Development at Merck, he explains what it takes to successfully develop an oncology therapeutic. Read the article here: https://lnkd.in/eCwvmyvV! #ClinicalTrials #DrugDevelopment #Keytruda

The antibody–drug conjugate (ADC) landscape is rapidly evolving and has become a significant therapeutic modality in oncology. The publication offers a nice overview of the ADC landscape. https://lnkd.in/eSGNKSEB

ESG401, a novel Trop2 ADC with SN38 conjugated to a humanized Trop2 mAb via a proprietary stable-cleavable linker at DAR8, is being evaluated in a Phase Ia/Ib ESG401-101 study to assess its efficacy in various subtypes of mBC in China. The results from this trial were presented at the ESMO - European Society for Medical Oncology 2024 conference. Maximize Your Knowledge with Expert Insights and Detailed Analysis through DelveInsight Business Research LLP's ESMO - European Society for Medical Oncology 2024 Exclusive Coverage @ https://lnkd.in/gRN_hK7Y #esmo #esmo2024 #esmoconference #conference #esmocoverage #detailedinsights #pharma #pharmaceutical

MiNK Therapeutics' Q1 report MiNK Therapeutics #Cancer #INKTCellPrograms #OncoDaily #Oncology #Q1Report

The 5th Cytokine-Based Drug Development Summit is almost upon us and we couldn’t be more pleased for our expert Cytokine team to be in attendance! Harvey Dennis, our expert Account Lead, is preparing to set the scene on Day 1 with a review of the cytokine therapeutics landscape and address the important question, Where Are We Now? Access the full presentation details here. 👉 https://ter.li/llav05 As we receive more clinical read-outs from leading IL-2 and IL-12 therapeutic developers, there has never been a better time to join our peers and accelerate your programs into the clinic. #cytokine #cytokines #cytokinedrugdevelopment #research #oncology #drugdevelopment

Ryvu Therapeutics is thrilled to announce a research collaboration with nCage Therapeutics to develop a next-generation antibody-drug conjugate (ADC) platform. Our Chief Scientific Officer, Krzysztof Brzozka, underlines: "This collaboration is an exciting opportunity to combine our small molecule expertise and experience with novel ADC payloads with the strong team at nCage, who are working on a truly novel delivery platform. We are encouraged by the growing field of next-generation ADCs and the potential for this collaboration to generate more effective and safer therapies." Ryvu and nCage foresee a long-term partnership to significantly enhance the TRAP cage for drug delivery, potentially leading to breakthrough oncology therapies.  Read more: https://lnkd.in/di7Xz5pg #RyvuTherapeutics #nCageTherapeutics #ADC #CancerResearch #NextGenTherapies #BiotechInnovation

Kyverna Therapeutics Signs a Collaboration Agreement with Stanford University to Evaluate KYV-101 for Multiple Sclerosis #kyvernatherapeutics #stanforduniversity #kyv101 #multiplesclerosis #pharma #collaboration #agreement #cancer #oncology #kysa7 #phase2 #phase1 #clinicaltrial #neurologicalautoimmunedisorders #anticd19 #rheumatologicalautoimmunedisorders

Global oncology biosimilars Market is projected to reach the value of $14.98 Billion by 2030 https://lnkd.in/g3sTWgDn #marketanalysis #marketresearch #marketresearchreports #businessintelligence